共 32 条
[1]
Gascon P(2010)Development of a new G-CSF product based on biosimilarity assessment Ann Oncol 21 1419-1429
[2]
Fuhr U(2012)Presently available biosimilars in hematology-oncology: G-CSF Target Oncol. 7 S29-S34
[3]
Sörgel F(2010)Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product BioDrugs. 24 347-357
[4]
Gascon P(2011)First experience of autologous peripheral blood stem cell mobilisation with biosimilar granulocyte colony-stimulating factor Adv Ther 28 304-310
[5]
Sörgel F(2012)Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients Bone Marrow Transplant 47 874-876
[6]
Lerch H(2013)Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment Br J Haematol 162 107-111
[7]
Lauber T(1982)Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 49-655
[8]
Lefrère F(2001)Randomized trial of filgrastim versus chemotherapy and filgrastim mobilisation of hematopoietic progenitor cells for rescue in autologous transplantation Blood 98 2059-2064
[9]
Brignier AC(2003)Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilisation of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies Transfusion. 43 50-57
[10]
Elie C(2008)Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilisation and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation Am J Hematol 83 644-648